KMB vs PRME · P/E 19, rev $8.35B vs rev $4.6M
Kimberly-Clark Corporation (KMB) versus Prime Medicine, Inc. Common Stock (PRME) — a side-by-side from cached financials, not a winner call.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.
KMB currently screens at market cap $32.88B and trailing P/E 19.2. PRME currently screens at market cap $570.8M.
Not investment advice. Open the KMB and PRME stock pages for the full models.
Not investment advice.